Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects by Malinovschi, A et al.
Exhaled nitric oxide levels and blood eosinophil counts
independently associate with wheeze and asthma events in
National Health and Nutrition Examination Survey subjects
Andrei Malinovschi, MD, PhD,a Jo~ao A. Fonseca, MD, PhD,b Tiago Jacinto, MSc,b Kjell Alving, PhD,c* and
Christer Janson, MD, PhDd* Uppsala, Sweden, and Porto, PortugalAbbreviations used
ATS: American Thoracic Society
B-Eos: Blood eosinophil count
BMI: Body mass index
ECP: Eosinophil cationic protein
FENO: Fraction of exhaled nitric oxide
ICS: Inhaled corticosteroid
NHANES: National Health and Nutrition Examination Survey
NO: Nitric oxide
OCS: Oral corticosteroidBackground: Fraction of exhaled nitric oxide (FENO) and blood
eosinophil count (B-Eos) values, markers of local and systemic
eosinophilic inflammation, respectively, are increased in asthmatic
patients. Little is known about the relation of these markers to
reportedwheezeandasthmaevents in a randompopulation sample.
Objectives: We sought to determine the individual and
independent values of B-Eos and FENO in relation to wheeze,
asthma diagnosis, and asthma events in a cross-sectional study.
Methods: FENO and B-Eos values were measured in 12,408
subjects aged 6 to 80 years from the National Health and
Nutrition Examination Survey 2007-2008 and 2009-2010.
Current wheeze and asthma diagnosis, as well as asthma attacks
and asthma-related emergency department (ED) visits within
the last 12 months, were assessed by means of questionnaires.
Results: Intermediate or high FENO values and intermediate or
high B-Eos values were independently associated with having
asthma, wheeze, and asthma attacks. However, only intermediate
and high B-Eos values were independently associated with
asthma-related ED visits. High FENO (>_50 ppb) and B-Eos
(>_500 cells/mm3) values rendered an adjusted odds ratio of
4.5 of having wheeze, 5.1 of having asthma, 5.4 for asthma
attacks, and 2.9 for asthma-related ED visits compared with
normal FENO (<25 ppb) and B-Eos (<300 cells/mm3) values.
Conclusions: Exhaled nitric oxide and B-Eos values offered
independent information in relation to the prevalence of wheeze,
asthma diagnosis, and asthma events in this random population
sample. The clinical importance of these findings in asthmatic
patients with regard to phenotyping and individualized
treatment, considering both local and systemic eosinophilic
inflammation, needs to be determined. (J Allergy Clin Immunol
2013;132:821-7.)
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Asthma is characterized by chronic airway inflammation,
variable airway obstruction, and airway hyperresponsiveness.1 In-
flammation is a major component of asthma, and medication to
control asthma is primarily anti-inflammatory. Nonetheless, it is
only during the past decade that inflammometry (ie, measurement
of inflammation to adjust anti-inflammatory therapy) has been in-
troduced.2 The fraction of exhaled nitric oxide (FENO) is a local
marker of airways inflammation, primarily that triggered by IL-
4 and IL-13.3Measurement of FENO is increasingly used in clinical
practice, and clinical guidelines on the use of FENO have recently
been published by the American Thoracic Society (ATS).4
Systemic eosinophilic inflammation, which is measured as
blood eosinophil count (B-Eos) or serum eosinophil cationic
protein (ECP) values, is also seen in asthmatic patients.5,6
Eosinophilia is primarily triggered by IL-5.7 Systemic eosino-
philic inflammation is often regarded as a spillover from the
inflamed airways. However, only moderate correlations have
been reported between the 2 components,8 and this view is now
being challenged by a model in which systemic inflammation
plays an independent role in patients with asthma and other
respiratory diseases.3,9,10 This new hypothesis is supported by
data from studies showing that systemic inflammation is not
always reduced by inhaled corticosteroids11,12 and that systemic
therapies, such as leukotriene receptor antagonists, might be
more effective in reducing systemic inflammatory markers.13,14
Furthermore, biological treatments directed at blocking IL-5
effectively decrease the signs of systemic inflammation, as
measured by B-Eos values, but does not change FENO values,15
whereas anti–IL-13 treatment reduces FENO values without
decreasing B-Eos values.16 Therefore it is reasonable to suggest
that assessing both local and systemic eosinophilic inflammation
in asthmatic patients would provide complementary information.
The aim of the present study was to assess the levels of local
(FENO) and systemic (B-Eos) TH2 cytokine–driven inflammation
in subjects from the US National Health and Nutrition821
TABLE I. Observed prevalence rates (percentages) of current asthma, wheeze, and asthma attack and asthma-related ED visits
according to different FENO and B-Eos values (normal-intermediate-high)
No. Current asthma P value* Current wheeze P value* Asthma attack P value*
Asthma-related
ED visit in last year P value*
Normal FENO value 10,131 7.1% <.001 11.7% <.001 3.4% <.001 1.1% <.001
Intermediate FENO value 1,688 10.7% 14.2% 5.6% 1.4%
High FENO value 589 22.9% 25.3% 13.7% 3.1%
Normal B-Eos value 9,036 6.8% <.001 10.7% <.001 3.0% <.001 0.8% <.001
Intermediate B-Eos value 2,499 10.3% 16.9% 5.8% 1.7%
High B-Eos value 873 18.1% 21.8% 10.8% 3.4%
*Pearson x2 test statistics and associated probabilities (P values) were calculated to evaluate differences among observed percentages across normal-intermediate-high categories of
FENO and B-Eos values.
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822 MALINOVSCHI ET ALExamination Survey (NHANES)17 and to investigate the relation
between these 2 inflammatory components in respect to self-
reported wheeze, physician-diagnosed asthma, asthma attacks,
and emergency department (ED) visits for asthma.METHODS
Ethics statement
The Ethics Review Board of the National Center for Health Statistics
Research approved all protocols. All participants provided written informed
consent.Study population
The study included 12,408 participants aged 6 to 80 years from the
NHANES 2007-2008 and NHANES 2009-2010 onwhom exhaled nitric oxide
(NO) measurements and blood differential counts had been performed.
Through the use of a complex probability cluster design, NHANES collects
nationally representative cross-sectional data on the health status of the
civilian, noninstitutionalized US population (http://www.cdc.gov/nchs/
nhanes.htm). Standardized health measurements were performed in mobile
examination centers.Exhaled NO
FENO values were measured with an electrochemical analyzer (NIOX
MINO; Aerocrine AB, Solna, Sweden) at an expiratory flow rate of 50 mL/s
in accordance with ATS/European Respiratory Society recommendations.18
The mean of 2 reproducible FENO measurements (within 2 ppb if levels were
<30 ppb or within 10% if levels were >30 ppb) was taken as the final result.
Two measurements of less than the detection limit of the device (<5 ppb)
were considered reproducible and given an arbitrary value of 3.5 ppb (1180
subjects). Two measurements of greater than the detection limit of the device
(>300 ppb) were also considered reproducible and given an arbitrary value of
301 ppb (1 subject).
In accordance with the ATS clinical guidelines on FENO measurement,4 we
have designated levels of less than 20 ppb (if <12 years of age) or less than 25
ppb as normal FENO levels (if >_12 years of age), levels of 20 or greater but less
than 35 ppb (if <12 years of age) and levels of 25 or greater but less than 50 ppb
(if >_12 years of age) as intermediate FENO levels, and levels of 35 ppb or
greater (if <12 years of age) or 50 ppb or greater (if >_12 years of age) as
high FENO levels.B-Eos
Blood differential counts were performed in NHANES 2007-2008 and
2009-2010 by using the Beckman Coulter HMX (Beckman Coulter, Fullerton,
Calif), a quantitative and automated hematologic analyzer and leukocyte
differential cell counter for in vitro diagnostic use in clinical laboratories.
A detailed description of the laboratory methods can be found on the
NHANES Web site (http://www.cdc.gov/nchs/nhanes.htm).The following cutoffs for B-Eos values were used: less than 300 cells/mm3
to define normal B-Eos values,19 300 cells/mm3 or greater but less than
500 cells/mm3 for intermediate values, and 500 cells/mm3 or greater for
high B-Eos values, because this is the limit for defining eosinophilia.20Current asthma and current wheeze
Current wheeze was defined as self-reported wheezing or whistling in the
chest during the last 12 months. Current asthma was defined as self-reported
physician-diagnosed asthma at any time of life together with a positive answer
to the following question: ‘‘Do you still have asthma?’’ Asthma attacks and
asthma-related ED visits during the last 12 months were self-reported.Hay fever
Self-reported hay fever episodes in the past 12 months were considered to
imply atopy.17Current use of inhaled or oral corticosteroids
Self-reported use of inhaled corticosteroids (ICSs) or oral corticosteroids
(OCSs) during the last 2 days before exhaled NOmeasurements was regarded
as current use of corticosteroids.Smoking history
Questions regarding cigarette use were only administered to participants
aged 20 years and older. We assumed that younger participants were never
smokers.17 A person was considered to be a never smoker if he or she had
smoked less than 100 cigarettes in his or her entire life. Subjects reporting
ever smoking at least 100 cigarettes during their lifetimes were classified,
based on self-reported current smoking, as exsmokers or current smokers.Body mass index
Height and weight were measured with digital stadiometers and scales, as
described on the NHANES Web site (http://www.cdc.gov/nchs/nhanes.htm).
Body mass index (BMI) was calculated as weight (kilograms) divided by
height squared (square meters).Statistical analyses
All the statistical analyses were conducted with STATA 12.1 software
(StataCorp, College Station, Tex). Pearson correlation was used to study the
relation between log-transformed FENO and B-Eos values. Pearson x2 test sta-
tistics and associated probabilities (P values) were calculated to evaluate dif-
ferences among observed percentages across normal-intermediate-high
categories of FENO and B-Eos values (Table I and see Tables E1 and E2 in
this article’s Online Repository at www.jacionline.org). Logistic regression
models, having current asthma, wheeze, asthma attacks, or asthma-related
ED visits as outcomes and FENO and B-Eos values as determinants, were
used to calculate odds ratios and CIs for prevalence rates of current asthma,
TABLE II. Factors associated with current asthma, wheeze, asthma attack, and asthma-related ED visit (adjusted odds ratio [95%
CI])
Current asthma Wheeze Asthma attack Asthma-related ED visit
Female sex 1.47 (1.27-1.72) 1.09 (0.97-1.23) 1.52 (1.24-1.88) 1.49 (1.04-2.14)
Age per 10 y 0.79 (0.75-0.82) 0.92 (0.89-0.95) 0.77 (0.72-0.82) 0.77 (0.68-0.86)
FENO value
Intermediate* 1.50 (1.22-1.85) 1.30 (1.09-1.54) 1.44 (1.08-1.91) 1.16 (0.70-1.91)
High* 2.37 (1.81-3.12) 2.23 (1.77-2.83) 2.32 (1.64-3.27) 1.12 (0.60-2.10)
B-Eos value
Intermediate* 1.26 (1.05-1.51) 1.39 (1.21-1.59) 1.60 (1.26-2.03) 1.71 (1.13-2.59)
High* 1.86 (1.45-2.38) 1.66 (1.35-2.04) 2.19 (1.59-3.01) 2.58 (1.53-4.35)
BMI per 5 units 1.20 (1.14-1.26) 1.19 (1.14-1.24) 1.20 (1.13-1.28) 1.22 (1.11-1.35)
Hay fever 2.46 (2.06-2.93) 2.39 (2.08-2.75) 2.45 (1.94-3.08) 1.12 (0.73-1.73)
Smoking history
Exsmoker 1.15 (0.91-1.46) 1.58 (1.32-1.89) 1.16 (0.83-1.61) 1.33 (0.76-2.34)
Current 1.23 (1.00-1.52) 3.66 (3.17-4.23) 1.33 (1.00-1.76) 1.41 (0.88-2.27)
Multiple logistic regression analyses were performed, and adjusted ORs (95% CIs) are presented. A relation is considered significant if the CI does not include 1.
*Compared with normal FENO or B-Eos values, respectively.
Compared with never smokers.
TABLE III. Adjusted odds ratios (95% CIs) of current asthma, wheeze, asthma attack, and asthma-related ED visit with increased
FENO and B-Eos values after adjusting for age, sex, BMI, hay fever, smoking history, and recent use of ICSs or OCSs
FENO value B-Eos value No. Current asthma Wheeze Asthma attack Asthma-related ED visit
Normal Normal 7,827 1 1 1 1
Normal Intermediate 1,806 1.31 (1.05-1.62) 1.40 (1.20-1.65) 1.56 (1.17-2.08) 1.51 (0.93-2.45)
Normal High 498 1.82 (1.30-2.55) 1.44 (1.10-1.89) 2.07 (1.34-3.20) 2.15 (1.08-4.28)*
Intermediate Normal 1,042 1.55 (1.19-2.04) 1.29 (1.03-1.62) 1.41 (0.95-2.09) 0.75 (0.32-1.78)
Intermediate Intermediate 478 2.00 (1.43-2.81) 1.74 (1.32-2.30) 2.34 (1.51-3.63) 2.33 (1.13-4.80)*
Intermediate High 168 2.27 (1.36-3.77) 2.26 (1.46-3.50) 3.01 (1.64-5.52) 3.43 (1.41-8.34)
High Normal 167 2.51 (1.50-4.18) 1.81 (1.15-2.84) 1.82 (0.84-3.98) 0.73 (0.10-5.45)
High Intermediate 215 2.41 (1.56-3.71) 2.86 (2.00-4.11) 3.72 (2.28-6.08) 1.86 (0.75-4.61)
High High 207 5.14 (3.54-7.45) 4.49 (3.18-6.33) 5.36 (3.42-8.42) 2.91 (1.36-6.20)
Multiple logistic regression analyses were performed, and adjusted ORs (95% CIs) are presented. All strata are compared with the stratum with normal FENO and B-Eos values.
A relation is considered significant if the CI does not include 1.
*Significance not consistent after adjusting for multiple comparisons (Holm method).
TABLE IV. Population characteristics (n 5 12,408)
Outcomes
Current asthma 1,032 (8.3%)
Wheeze during last year 1,577 (12.7%)
Asthma attacks in last year 506 (4.1%)
Asthma-related ED visits in last year 148 (1.2%)
Dependent variables
FENO value (ppb) 13 (3.5-301)
B-Eos value (3 109/L) 0.2 (0-8.4)
Independent variables
Age (y) 36 (6-80)
Female sex 6,080 (49%)
BMI (kg/m2) 26.3 (12.5-84.9)
Past smoking 2,087 (17.2%)*
Current smoking 2,087 (17.2%)*
Hay fever 1,688 (13.7%)
Use of ICSs or OCSs in last 2 d 491 (4.0%)
Values are presented as medians (ranges) or numbers (percentages).
*Calculated for subjects older than 20 years for whom data were available on
cigarette use.
FIG 1. FENO values in subjects with normal, intermediate, or high B-Eos
values. Line, Median; box, 25th-75th percentile; whiskers, 10th and 90th
percentiles; outliers, below 10th and above 90th percentiles.
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E3 and E4 in this article’s Online Repository at www.jacionline.org). FENO and
B-Eos values were included in the regression models a priori. A similar
model with the same outcomes (current asthma, wheeze, asthma attacks, orasthma-related ED visits) and a combination of FENO and B-Eos value cate-
gories as a determinant was used in Table III and Table E5 in this article’s On-
line Repository at www.jacionline.org. These multiple logistic regression
models included adjustments for age, sex, BMI, hay fever, current smoking,
and recent use of inhaled or oral corticosteroids. Holm adjustments for multi-
ple comparisons were also reported in the models described in Tables III and
E5. Because atopy is related to FENO values,21 a multiple logistic regression
FIG 2. Prevalence of current asthma (left upper panel), current wheeze (right upper panel), asthma attacks
(left lower panel), and ED visits (right lower panel) according to normal, intermediate, or high FENO and
blood eosinophil values. The number of subjects in each category is presented in the table above.
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also reported (see Table E5). A P value of less than .05 was considered
statistically significant.
RESULTS
A total of 12,408 subjects have performed FENO measurements
and blood differential counts and were included in the study. The
characteristics of these subjects are presented in Table IV.
There was a weak but statistically significant correlation
between the FENO and B-Eos values (Pearson r 5 0.22,
P < .001). The explanatory value (R2) was 4.0%. FENO values,
according to different (normal-intermediate-high) B-Eos value
categories, are depicted in Fig 1, and the explanatory value (R2)
of this model was 4.6%. The explanatory value was slightly
higher when looking at the subgroups of subjects with current
asthma (n 5 994, R2 5 0.13, P < .001) or wheeze (n 5 1519,
R2 5 0.09, P < .001).
The prevalence of current asthma and wheeze increased
progressively with increased FENO values (Table I). A similar
increase in current asthma and wheeze was observed with
increased B-Eos values (all P < .001, Table I). Also, the preva-
lence of asthma attacks and asthma-related ED visits increased
with higher FENO and B-Eos values, respectively (Table I). These
results were consistent when separately analyzing children
(see Table E1) and adults (see Table E2).
When looking at the 2 markers in combination, the prevalence
of current asthma increased with increased FENO and B-Eosvalues from 6.2% in the group with normal FENO and B-Eos
values to 33.3% in the group with high FENO and B-Eos values
(Fig 2). Having intermediate or high FENO values and intermedi-
ate or high B-Eos values was independently associated with
having asthma, wheeze, and asthma attacks (Table II). However,
only intermediate and high B-Eos values were independently
associated with asthma-related ED visits. Additional risk factors
were high BMI, hay fever, and current smoking (Table II). Similar
relations were found in children (see Table E3) and adults
(see Table E4). No significant interactions with age (children vs
adults) were found when analyzing the relation between having
intermediate and high FENO values or intermediate and high
B-Eos values and wheezing, asthma, and asthma events.
An increased probability of having current asthma and wheeze
was found with increasing FENO values by different strata of
B-Eos values (Fig 3), with the highest probability in the group
with high B-Eos values. A significantly increased probability of
asthma attacks was found with increased FENO values only in
subjects with intermediate or high B-Eos values, whereas a
significantly increased probability of asthma-related ED visits
was found only in subjects with high B-Eos values.
The risk (odds ratio) of having wheeze or current asthma
increased approximately 5-fold in subjects with both high FENO
and high B-Eos values compared with subjects with normal
FENO and normal B-Eos values after adjustment for other risk
factors (Table III and see Table E5 without adjustment for hay
fever). The corresponding odds ratios for asthma attacks and
FIG 3. Probability of current asthma (left upper panel), current wheeze (right upper panel), asthma attacks
(left lower panel), and ED visits (right lower panel) with increased FENO values plotted for each stratum of
B-Eos values: normal (continuous line), intermediate (dashed line), and high (long-dashed line).
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tively. The risk of having an asthma-related ED visit was not sig-
nificantly increased in subjects with high FENO values if they had
normal or intermediate B-Eos values, whereas high B-Eos values
were related to ED visits regardless of FENO values (Table III).
A consistent effect of having both high FENO and high B-Eos
values on all the asthma variables was seen after exclusion of sub-
jects taking ICSs or OCSs and after the additional exclusion of
subjects reporting hay fever. Furthermore, a consistent effect on
wheeze was seen after excluding current asthma (Fig 4).DISCUSSION
The main finding from this study in a large population was that
FENO and B-Eos values were each independently associated with
current asthma, wheeze, and asthma attacks, as well as being as-
sociated in an additive manner. Our data support the view that
these 2 markers cannot be used interchangeably but should be
used in combination. However, it must be recognized that this
is a population-based study with the main purpose of identifying
new information regarding these 2 inflammatory components and
not a study for determining the diagnostic accuracy of these
methods. Such a study should be performed in a more relevant
population, such as in subjects undergoing clinical investigations
because of suspected asthma.
In the present study, asthma and wheeze were 3 times more
prevalent among subjects with high exhaled NO values thanamong subjects with normal values, and the prevalence was
increased to a similar level among those with high B-Eos values.
Several studies have previously found such associations for each
of these markers separately,22 but to our knowledge, no earlier
study has evaluated the additive predictive value of systemic eo-
sinophil markers and exhaled NO values.
One reason why few have tested the predictive value of the
combination of FENO and B-Eos might be that these markers are
generally considered to measure the same inflammatory compo-
nent of asthma, usually defined as ‘‘eosinophilic airway inflam-
mation.’’4 However, in the present study the correlation between
FENO and B-Eos values was weak, with an explanatory value of
only approximately 4%, which is in line with the previously re-
ported weak-to-moderate correlations between FENO and eosino-
phil values in blood or sputum8,23 or between blood and sputum
eosinophil values.24 This, together with the clear-cut additive ef-
fect of these 2markers on the risk for asthma, wheeze, and asthma
attacks in our study, indicates that they represent 2 different in-
flammatory pathways with separate trigger mechanisms.
Interestingly, increased blood eosinophil values were more
important in relation to asthma-related ED visits in this material,
which is in line with the recent findings of severe asthma
exacerbation reductions in subjects with severe eosinophilic
asthma25 receiving anti–IL-5 treatment, which primarily targets
the systemic eosinophilic inflammation. A previous study per-
formed in children reported a relation between serum ECP values
and asthma attacks,26 whereas a Dutch registry study reported a
FIG 4. Probability (aOR [95% CI]) of current asthma (left upper panel), current wheeze (right upper panel),
asthma attacks (left lower panel), and ED visits (right lower panel) after exclusion of subjects taking ICSs
or OCSs, those with hay fever, and those with current asthma (the latter only for the analyses in the right
upper panel) in subjects with both high FENO and high B-Eos values (compared with subjects with normal
FENO and normal B-Eos values).
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ity.27 FENO signals local IL-4/IL-13–mediated mechanisms in
the bronchial mucosa that are primarily triggered by aeroallergen
exposure.3 An increase in FENO values seems to precede moder-
ate, but not severe, asthma exacerbations.28 We have recently
reported that guiding anti-inflammatory treatment in asthma
based on FENO measurement resulted in a reduction of moderate,
but not severe, exacerbations.29 Severe exacerbations are primar-
ily related to viral infections.30 Increased baseline sputum
eosinophil values were related to more severe symptoms in
respect to experimental rhinovirus infection,31 which might
support our findings on the relation between increased B-Eos
values and asthma-related ED visits.
The general view has been that eosinophilic asthma can be
identified by at least 1 of the following: increased FENO, increased
sputum eosinophil, or increased blood eosinophil values.18,25 Our
results indicate that this view is valid only at the group level and
not at the individual level. At the individual level, a combination
of markers is preferred. Furthermore, from recent asthma studies
in which the clinical effect of new biological drugs has been eval-
uated, particularly anti–IL-515 and anti–IL-13,16 it is evident that
exhaled NO and blood eosinophil values signal different cytokine
mechanisms.3 Blood eosinophilia is primarily driven by IL-57 and
might be triggered also, for example, by subchronic or persistent
rhinovirus infections32 or in connection to chronic rhinosinusitis
with or without polyposis33 in addition to aeroallergen exposure.Taken together, both local and systemic TH2 cytokine–driven
mechanisms, partly with different triggers, seem to be involved
in ‘‘eosinophilic’’ asthma, suggesting a ‘‘double-hit’’ mechanism
for the development of respiratory symptoms and asthma.
One advantage of FENO and B-Eos measurements is that these
methods are relatively inexpensive and that the sampling causes
less discomfort for the patients than other methods of assessing
inflammation, such as induced sputum or bronchoscopy. During
recent years, there has been a great interest in identifying different
phenotypes of asthma to develop more targeted therapeutic
interventions.33 Our data indicate that using FENO and B-Eos
measurements in combination might be a cost-effective way of
gathering phenotypic information in asthmatic patients34 and
that the systemic eosinophilic component might be more related
to severe asthma exacerbations, as discussed above.
Even though the combination of high FENO and B-Eos values
was strongly related to current asthma,wheeze, and asthmaattacks,
it should be noted that a significant proportion of subjects in this
group reported neither. However, it is possible that asymptomatic
subjects with the combination of high FENO and high B-Eos values
constitute a group with a very high risk of asthma because in-
creased B-Eos values have been related to future development of
asthma in a longitudinal study35 and increased serum ECP levels
were related to the incidence of asthma in a population of patients
with allergic rhinitis.36 Similarly, increased FENO values have been
shown to indicate increased risk of asthma or wheeze.37,38
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used are both markers of the eosinophilic type of inflammation,
and therefore other inflammatory patterns, such as neutrophilic
inflammation, would not be identified. However, in the general
asthmatic population the phenotype characterized by eosinophilic
activation predominates.33 Furthermore, the main result regard-
ing the independent and additive value of the 2 biomarkers in de-
tecting asthma or wheeze would probably not have been affected
by the presence of noneosinophilic asthma. No data on IgE sensi-
tization are available for the subjects included in the present study.
However, the additive value of FENO and B-Eos measurements for
predicting asthma or wheeze was confirmed, even after we ex-
cluded subjects with reported hay fever as a proxy for IgE
sensitization.
In conclusion, information from this large population study
shows that it might be advantageous to assess both local inflam-
mation in the airways (FENO) and systemic eosinophilic inflam-
mation (eg, B-Eos) to identify subjects with wheeze and asthma
and patients at risk of asthma exacerbations. Our findings support
the view that both local and systemic TH2 cytokine–driven mech-
anisms are important for the development of respiratory symp-
toms and clinical asthma, but the clinical use of the
combination of these markers warrants further study.
Clinical implications: Local and systemic TH2 cytokine–driven
mechanisms independently trigger the development of respira-
tory symptoms and clinical asthma. The clinical importance of
assessing both these components for individualizing treatment
decisions warrants further study.
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TABLE E1. Observed prevalence rates of current asthma, wheeze, and asthma events according to different FENO and B-Eos values
(normal-intermediate-high [percentages]) among NHANES children (n 5 3172)
No. Current asthma P value* Current wheeze P value* Asthma attack P value*
Asthma-related
ED visit in last year P value*
Normal FENO value 2,535 9.1% <.001 8.3% <.001 4.2% <.001 1.4% .03
Intermediate FENO value 378 10.7% 14.8% 7.7% 2.2%
High FENO value 70 27.0% 24.7% 17.4% 3.5%
Normal B-Eos value 9,036 8.5% <.001 7.7% <.001 3.4% <.001 1.0% <.001
Intermediate B-Eos value 2,499 14.7% 14.0% 8.1% 2.7%
High B-Eos value 873 23.0% 20.7% 15.1% 3.7%
*P values for Pearson x2 test.
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TABLE E2. Observed prevalence rates of current asthma, wheeze, and asthma events according to different FENO and B-Eos values
(normal-intermediate-high [percentage]) among NHANES adults (n 5 9223)
No. Current asthma P value* Current wheeze P value* Asthma attack P value*
Asthma-related
ED visit in last year P value*
Normal FENO value 2,535 6.3% <.001 12.9% <.001 3.0% <.001 0.9% .006
Intermediate FENO value 378 9.6% 14.1% 4.7% 1.2%
High FENO value 70 19.7% 25.8% 10.3% 2.7%
Normal B-Eos value 9,036 6.3% <.001 11.6% <.001 2.8% <.001 0.8% <.001
Intermediate B-Eos value 2,499 8.8% 17.9% 5.0% 1.4%
High B-Eos value 873 14.8% 22.5% 7.9% 3.3%
*P values for Pearson x2 test.
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TABLE E3. Factors associated with current asthma, wheeze, and asthma events (adjusted odds ratio [95% CI]) in NHANES children
(n 5 3149)
Current asthma Wheeze Asthma attack Asthma-related ED visit
Female sex 0.89 (0.69-1.15) 0.78 (0.61-1.01) 0.78 (0.55-1.10) 0.78 (0.43-1.42)
Age per 10 y 0.73 (0.47-1.13) 0.78 (0.50-1.20) 0.44 (0.25-0.80) 0.24 (0.08-0.66)
FENO value
Intermediate* 1.41 (0.98-2.05) 1.54 (1.08-2.21) 1.56 (0.95-2.55) 1.15 (0.47-2.82)
High* 2.34 (1.57-3.49) 2.29 (1.54-3.41) 2.61 (1.60-4.27) 1.25 (0.51-3.05)
B-Eos value
Intermediate* 1.38 (1.00-1.89) 1.37 (1.01-1.88) 1.65 (1.08-2.52) 2.00 (0.98-4.06)
High* 1.81 (1.23-2.67) 1.61 (1.10-2.38) 2.36 (1.45-3.83) 2.07 (0.89-4.85)
BMI per 5 units 1.36 (1.22-1.53) 1.25 (1.12-1.41) 1.38 (1.18-1.60) 1.48 (1.15-1.90)
Hay fever 1.86 (1.33-2.93) 2.95 (2.18-4.00) 1.76 (1.15-2.69) 0.78 (0.34-1.81)
Multiple logistic regression analyses were performed, and adjusted ORs (95% CIs) are presented. A relation is significant if the CI does not include 1.
*Compared with normal FENO or B-Eos values, respectively.
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TABLE E4. Factors associated with current asthma, wheeze and asthma events (adjusted odds ratio [95% CI]) in NHANES adults
(n 5 8838)
Current asthma Wheeze Asthma attack Asthma-related ED visit
Female sex 2.07 (1.70-2.52) 1.22 (1.06-1.40) 2.34 (1.78-3.08) 2.24 (1.37-3.67)
Age per 10 y 0.90 (0.84-0.95) 0.97 (0.93-1.02) 0.85 (0.78-0.93) 0.86 (0.74-1.00)
FENO value
Intermediate* 1.61 (1.25-2.08) 1.24 (1.02-1.51) 1.47 (1.03-2.09) 1.26 (0.69-2.33)
High* 2.42 (1.63-3.59) 2.19 (1.61-2.97) 2.15 (1.29-3.57) 1.20 (0.49-2.92)
B-Eos value
Intermediate* 1.15 (0.91-1.44) 1.35 (1.16-1.58) 1.51 (1.12-2.04) 1.49 (0.89-2.52)
High* 1.68 (1.19-2.38) 1.53 (1.19-1.98) 1.65 (1.04-2.63) 2.58 (1.30-5.15)
BMI per 5 units 1.23 (1.16-1.30) 1.21 (1.16-1.27) 1.22 (1.13-1.32) 1.25 (1.11-1.40)
Hay fever 2.70 (2.19-3.32) 2.24 (1.91-2.62) 2.72 (2.06-3.59) 1.24 (0.73-2.08)
Smoking history
Exsmoker 1.31 (1.03-1.67) 1.68 (1.41-2.02) 1.30 (0.93-1.82) 1.46 (0.81-2.62)
Current 1.63 (1.29-2.05) 4.12 (3.51-4.84) 1.63 (1.20-2.22) 1.76 (1.03-2.99)
Multiple logistic regression analyses were performed, and adjusted ORs (95% CIs) are presented. A relation is significant if the CI does not include 1.
*Compared with normal FENO or B-Eos values, respectively.
Compared with never smokers.
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TABLE E5. Adjusted odds ratios (95% CIs) of current asthma, wheeze, asthma attack, and asthma-related ED visit with increased
FENO and B-Eos values after adjusting for age, sex, BMI, smoking history, and recent use of ICSs or OCSs
FENO value B-Eos value Asthma Wheeze Asthma attack Asthma-related ED visit
Normal Normal 1 1 1 1
Normal Intermediate 1.35 (1.09-1.67) 1.44 (1.23-1.68) 1.61 (1.21-2.15) 1.52 (0.94-2.48)
Normal High 1.87 (1.34-2.61) 1.48 (1.13-1.94) 2.13 (1.38-3.28) 2.17 (1.09-4.32)*
Intermediate Normal 1.65 (1.26-2.16) 1.35 (1.08-1.69) 1.50 (1.02-2.22)* 0.76 (0.32-1.81)
Intermediate Intermediate 2.24 (1.60-3.12) 1.90 (1.44-2.50) 2.62 (1.70-4.04) 2.37 (1.15-4.87)*
Intermediate High 2.59 (1.57-4.26) 2.68 (1.76-4.08) 3.51 (1.94-6.34) 3.52 (1.45-8.50)
High Normal 2.76 (1.66-4.59) 1.96 (1.25-3.08) 1.97 (0.90-4.31) 0.74 (0.10-5.51)
High Intermediate 2.61 (1.71-3.99) 3.00 (2.10-4.28) 4.08 (2.52-6.59) 1.90 (0.77-4.69)
High High 5.86 (4.07-8.44) 4.99 (3.56-7.00) 6.22 (3.99-9.68) 2.96 (1.39-6.30)
Multiple logistic regression analyses were performed, and adjusted ORs (95% CIs) are presented. All strata are compared with the stratum with normal FENO and B-Eos values.
A relation is significant if the CI does not include 1.
*Significance not consistent after adjusting for multiple comparisons (Holm method).
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